Qsemble Capital Management LP Makes New $995,000 Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Qsemble Capital Management LP bought a new position in Charles River Laboratories International, Inc. (NYSE:CRL) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,672 shares of the medical research company’s stock, valued at approximately $995,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Headlands Technologies LLC bought a new position in Charles River Laboratories International in the 1st quarter worth about $41,000. VisionPoint Advisory Group LLC grew its position in Charles River Laboratories International by 45.1% in the 4th quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock worth $49,000 after purchasing an additional 65 shares during the last quarter. Brown Brothers Harriman & Co. grew its position in Charles River Laboratories International by 76.0% in the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after purchasing an additional 95 shares during the last quarter. GAMMA Investing LLC bought a new position in Charles River Laboratories International in the 4th quarter worth about $62,000. Finally, Bruce G. Allen Investments LLC bought a new position in Charles River Laboratories International in the 4th quarter worth about $70,000. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on CRL. Argus reiterated a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. Robert W. Baird decreased their price objective on shares of Charles River Laboratories International from $271.00 to $239.00 and set an “outperform” rating for the company in a report on Wednesday, July 10th. The Goldman Sachs Group began coverage on shares of Charles River Laboratories International in a report on Thursday, June 6th. They issued a “buy” rating and a $290.00 price objective for the company. Mizuho began coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They issued a “neutral” rating and a $235.00 price objective for the company. Finally, TD Cowen decreased their price objective on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a report on Monday, May 13th. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and a consensus price target of $252.29.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction on Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Up 5.1 %

Charles River Laboratories International stock traded up $11.06 during midday trading on Tuesday, reaching $227.31. The stock had a trading volume of 468,665 shares, compared to its average volume of 535,190. The firm’s fifty day simple moving average is $214.09 and its two-hundred day simple moving average is $230.47. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37. The firm has a market cap of $11.71 billion, a price-to-earnings ratio of 25.44, a PEG ratio of 2.05 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 11 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).